Anticoagulant, antiplatelet, anticoagulant, antithrombotic
Showing 1 - 25 of 1,966
Non-valvular Atrial Fibrillation Trial in Hangzhou (Dual antiplatelet, Novel oral anticoagulant)
Recruiting
- Non-valvular Atrial Fibrillation
- Dual antiplatelet
- Novel oral anticoagulant
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine at Zhejiang Universi
Feb 27, 2023
Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome Trial in Beijing (Aspirin + Clopidogrel +
Not yet recruiting
- Coronary Artery Disease
- +2 more
- Aspirin + Clopidogrel + Rivaroxaban
- Aspirin + Clopidogrel
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences, Fuwai Hospital
Dec 5, 2022
Venous Thromboembolic Disease Trial in France (Full-dose anticoagulant therapy (AC), Antiplatelet therapy (AP))
Not yet recruiting
- Venous Thromboembolic Disease
- Full-dose anticoagulant therapy (AC)
- Antiplatelet therapy (AP)
-
Amiens, France
- +27 more
Jan 13, 2023
Anticoagulant Drug Intervention on Postoperative MALE and MACE
Recruiting
- Anticoagulant Drugs
- +2 more
- anticoagulant or antiplatelet drugs
-
Hangzhou, None Selected, ChinaFirst Affiliated Hospital of Zhejiang University
May 8, 2023
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease Trial in Clermont-Ferrand (monitoring the use of anticoagulant and/or
Not yet recruiting
- Hereditary Hemorrhagic Telangiectasia
- Rendu Osler Disease
- monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
-
Clermont-Ferrand, FranceCHU clermont-ferrand
Nov 29, 2022
Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction Trial in Hangzhou (Rivaroxaban, Aspirin)
Recruiting
- Deep Vein Thrombosis
- +4 more
-
Hangzhou, Zhejiang, ChinaThe First Affliated Hospital, Zhejiang University, School of Med
Dec 13, 2021
Cerebral Hemorrhage, Intracranial Hemorrhages, Atrial Fibrillation Trial in Copenhagen, Oslo, Umeå (Antithrombotic Agent)
Recruiting
- Cerebral Hemorrhage
- +4 more
- Antithrombotic Agent
-
Copenhagen, Denmark
- +2 more
Sep 7, 2021
Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid Trial (Anticoagulant Oral, Anticoagulation combined with
Not yet recruiting
- Acute Ischemic Stroke
- +3 more
- Anticoagulant Oral
- Anticoagulation combined with antiplatelet therapy
- (no location specified)
Sep 21, 2023
Ischemic Stroke, Atrial Fibrillation, Atherothrombosis Trial in Kobe, Osaka (Oral Anticoagulant, Antiplatelet Drug)
Recruiting
- Ischemic Stroke
- +2 more
- Oral Anticoagulant
- Antiplatelet Drug
-
Kobe, Hyogo, Japan
- +1 more
Oct 8, 2020
Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding Trial in Ann Arbor (Clinician
Completed
- Upper Gastrointestinal Bleeding
- +2 more
- Clinician Notification with Nurse Facilitation (CNNF)
- Wait list control
-
Ann Arbor, MichiganUniversity of Michigan
Jan 4, 2023
Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation Trial (First month DAPT, First month standard therapy)
Not yet recruiting
- Acute Coronary Syndrome
- +10 more
- First month DAPT
- First month standard therapy
- (no location specified)
Apr 16, 2021
Coronary Artery Disease Trial in Seoul (Clopidogrel treatment group, No antiplatelet or anticoagulant group)
Recruiting
- Coronary Artery Disease
- Clopidogrel treatment group
- No antiplatelet or anticoagulant group
-
Seoul, Other, Korea, Republic ofSeoul National University Hospital
May 9, 2023
Better antithrOmbotic Strategies in AF (RAINBOW-AF)
Not yet recruiting
- Atrial Fibrillation
- Anticoagulant Therapy
- (no location specified)
May 18, 2022
COVID-19 in Anticoagulated or Antiaggregated Patients
Completed
- Covid19
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
-
Barcelona, Catalonia, SpainHospital de la Santa Creu i Sant Pau
Aug 18, 2020
Aortic Valve Disease Trial in Paris (Apixaban 5 MG Oral Tablet, warfarin with an objective of INR target of 2.5 (range:
Not yet recruiting
- Aortic Valve Disease
- Apixaban 5 MG Oral Tablet
- warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
-
Paris, FranceService de Cardiologie Hôpital Lariboisière
Jan 24, 2023
Subject Under Anticoagulant Trial in Marseille (an observational study)
Recruiting
- Subject Under Anticoagulant
- an observational study
-
Marseille, FranceAssistance Publique Hopitaux de Marseille
Aug 12, 2022
Antithrombotic Agents Management Trial in Ioannina
Completed
- Antithrombotic Agents Management
-
Ioannina, GreeceUniversity Hospital of Ioannina
Feb 19, 2021
Mild Head Injury, Antiplatelets, and Anticoagulants
Completed
- Craniocerebral Trauma
- Cerebral Hemorrhage
- direct anticoagulant
- +2 more
-
Roma, Rm, ItalyFondazione Policlinico Universitario Agostino Gemelli - IRCCS
Mar 29, 2022
Stroke, Carotid Web Trial in Barcelona (Antiplatelet Drug, Anticoagulant, Endovascular)
Recruiting
- Stroke
- Carotid Web
- Antiplatelet Drug
- +3 more
-
Barcelona, SpainHospital de la Santa Creu i Sant Pau
Jul 28, 2022
Acute Coronary Syndrome, Coronary Artery Ectasia Trial in Mexico City (Rivaroxaban 15 MG, Acetylsalicylic acid 100mg,
Recruiting
- Acute Coronary Syndrome
- Coronary Artery Ectasia
- Rivaroxaban 15 MG
- +2 more
-
Mexico City, Mexico
- +1 more
Jan 31, 2022
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Peripheral Artery
Recruiting
- Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
- Peripheral Artery Disease
- Antiplatelet Drug
-
Moscow, Russian FederationNational Medical Research Center for Cardiology, Ministry of Hea
Apr 14, 2020
Cryptogenic Ischemic Stroke, Patent Foramen Ovale Trial in France (Transcatheter PFO closure, Oral Anticoagulant, Direct-Acting,
Not yet recruiting
- Cryptogenic Ischemic Stroke
- Patent Foramen Ovale
- Transcatheter PFO closure
- +2 more
-
Amiens, France
- +30 more
May 20, 2022